Treatment of acute herpes zoster, treatment/f suppression of recurrent genital herpes in immunocompetent patients, treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients.
In herpes zoster 500 mg every 8 hours for 7 days. In immunocompromised patients 500mg tid for 10 days. In first episode of genital herpes 250 mg tid for 5 days.In recurrent genital herpes 125 mg twice daily for 5 days and in immunocompromised patients 500 mg tid for 7 days. In suppression of recurrent genital herpes 250 mg twice daily for up to 1 year. in recurrent orolabial or genital herpes simplex infections, the dose is 500mg twice daily for 7 days. Reduction of dosage is recommended in redu
No data on the safety of the drug in infants. The pharmacokinetics of famciclovir or penciclovir has not been evaluated in patients below 18years. Dosage adjustment is in needed in renal impairment.
No life threating reactions. Headache, paresthesia, migraine, nausea, diarrhea, vomiting, flatulence, abdominal pain, fatigue, pruritus, rash, and dysmenorrhoea.
Clinically significant adverse drug interactions have not been reported. Simultaneous administration with other antiviral compounds such as acyclovir, ganciclovir, or foscarnet gives synergistic effects.